GSK Archives - Lets Talk Health

GSK to spend $1 billion to lift stakes in India, Nigeria units

11/26/2012 majac Your Health Matters

MUMBAI (Reuters) – GlaxoSmithKline Plc plans to spend more than $1 billion to raise stakes in its Indian and Nigerian consumer healthcare arms, as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health footprint. The deals are the latest of several by GSK, which is reducing its reliance on traditional prescription drug markets in Western economies where sales are slowing. GSK said on Monday it will buy up to an additional 31.8 percent stake in India's GlaxoSmithKline Consumer Healthcare Ltd for about $940 million by paying 3,900 rupees ($70. …

GSK, health, India, Nigeria

GlaxoSmithKline to reveal more drug secrets

10/11/2012 majac Your Health Matters

LONDON (Reuters) – GlaxoSmithKline, criticized in the past for keeping important information about its medicines to itself, is to lift the lid on more of its drug secrets. Three months after GSK was fined $3 billion for fraud in the United States, where prosecutors accused it of concealing safety issues, chief executive Andrew Witty said on Thursday detailed data from its clinical trials would be made available to other researchers. That would include anonymised patient-level results that sit behind clinical trials of approved and failed drugs. …

Andrew Witty, GSK, United States

GSK sells Australian drugs to Aspen for $270 mln

08/15/2012 majac Your Health Matters

JOHANNESBURG/LONDON (Reuters) – GlaxoSmithKline advanced its clear-out of non-core drugs on Wednesday with a deal to sell 25 older brands marketed in Australia to South Africa's Aspen Pharmacare for 172 million pounds. Andrew Witty, chief executive of Britain's biggest drugmaker, said last month during quarterly results that he was looking for further ways to simplify the GSK business, following previous divestments in consumer health. The old Australian brands being bought by Aspen include herpes treatment Valtrex, epilepsy drug Lamictal and the antibiotic Amoxil. …

Andrew Witty, Aspen Pharmacare, Australia, GSK

GSK wins $3.0-bln takeover of Human Genome Sciences

07/16/2012 majac Your Health Matters

British drugmaker GlaxoSmithKline on Monday clinched the takeover of US research partner Human Genome Sciences Inc. after increasing its bid to $3.0 billion (2.4 billion euros).

GSK, Human Genome Sciences, US

GSK says new data support filing of diabetes drug

04/03/2012 majac Your Health Matters

LONDON (Reuters) – GlaxoSmithKline will push ahead with plans to file its experimental once-weekly diabetes drug albiglutide for regulatory approval, following the read-out from a series of clinical trials. Albiglutide belongs to the same class of injectable GLP-1 medicines as Novo Nordisk’s Victoza and Byetta, from Amylin Pharmaceuticals and Eli Lilly. Byetta was the first drug of the type. Last November, GSK reported that albiglutide cut blood sugar less than daily Victoza in the first of a series of late-stage clinical trials, dimming its prospects in an increasingly competitive market. …

GLP, GSK, Last November

Study finds early potential in GSK leukaemia drug (Reuters)

10/02/2011 majac Your Health Matters

Reuters – British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) — the most common form of leukemia in babies.

GSK, MLL